Maria Luisa Agüera

Maria Luisa Agüera

Auto-generated profile, based on publicly available information

Maria Luisa Agüera

Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PVPeter Vink
Peter Vink
JTJosep Maria Ramon Torrell
Josep Maria Ramon Torrell
AFAna Isabel Sánchez Fructuoso
Ana Isabel Sánchez Fructuoso
SKSung-Joo Kim
Sung-Joo Kim
SKSang-Il Kim
Sang-Il Kim
LOLidia Oostvogels
Lidia Oostvogels
Background: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. Methods: In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1–2 months (M) apart 4–18M posttransplant. Anti–glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates were assessed at 1M post–dose 1, and 1M and 12M post–dose 2. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Solicited general symptoms and unsolicited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential immune-mediated diseases (pIMDs) were recorded up to 12M post–dose 2. Results: Two hundred sixty-four participants (RZV: 132; placebo: 132) were enrolled between March 2014 and April 2017. gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across postvaccination time points and persisted above prevaccination baseline 12M post–dose 2. Local AEs were reported more frequently by RZV than placebo recipients. Overall occurrences of renal function changes, rejections, unsolicited AEs, serious AEs, and pIMDs were similar between groups. Conclusions: RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M postvaccination. No safety concerns arose. Clinical Trials Registration: NCT02058589.

1 November 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
MNM D Navarro
M D Navarro
MLM. López-Andréu
M. López-Andréu
ARA. Rodríguez-Benot
A. Rodríguez-Benot
MAM.L. Agüera
M.L. Agüera
DCD. Del Castillo
D. Del Castillo
PAP. Aljama
P. Aljama

1 April 2004 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
MEMario Espinosa
Mario Espinosa
AMAlejandro Martıén-Malo
Alejandro Martıén-Malo
RORaquel Ojeda
Raquel Ojeda
RSRafael Santamaria
Rafael Santamaria
SSSagrario Soriano
Sagrario Soriano
PAPedro Aljama
Pedro Aljama

1 March 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MFMario Fernández-Ruiz
Mario Fernández-Ruiz
EGE. Giménez
E. Giménez
VVV. Vinuesa
V. Vinuesa
TRT. Ruiz-Merlo
T. Ruiz-Merlo
PPP. Parra
P. Parra
CRCristian Rodelo-Haad
Cristian Rodelo-Haad

1 April 2017 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
ACAndrés Carmona
Andrés Carmona
MAMaria L. Agüera
Maria L. Agüera
CLCarlos Luna-Ruiz
Carlos Luna-Ruiz
PBPaula Buendía
Paula Buendía
LCLaura Calleros
Laura Calleros
JAJulia Carracedo Añon
Julia Carracedo Añon
Patients with Stage 5 chronic kidney disease who are on hemodialysis (HD) remain in a chronic inflammatory state, characterized by the accumulation of uremic toxins that induce endothelial damage and cardiovascular disease (CVD). Our aim was to examine microvesicles (MVs), monocyte subpopulations, and angiopoietins (Ang) to identify prognostic markers in HD patients with or without diabetes mellitus (DM). A total of 160 prevalent HD patients from 10 centers across Spain were obtained from the Biobank of the Nephrology Renal Network (Madrid, Spain): 80 patients with DM and 80 patients without DM who were matched for clinical and demographic criteria. MVs from plasma and several monocyte subpopulations (CD142+/CD16+, CD14+/CD162+) were analyzed by flow cytometry, and the plasma concentrations of Ang1 and Ang2 were quantified by ELISA. Data on CVD were gathered over the 5.5 yr after these samples were obtained. MV level, monocyte subpopulations (CD14+/CD162+ and CD142+/CD16+), and Ang2-to-Ang1 ratios increased in HD patients with DM compared with non-DM patients. Moreover, MV level above the median (264 MVs/µl) was associated independently with greater mortality. MVs, monocyte subpopulations, and Ang2-to-Ang1 ratio can be used as predictors for CVD. In addition, MV level has a potential predictive value in the prevention of CVD in HD patients. These parameters undergo more extensive changes in patients with DM.

1 November 2015 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PPP. Pérez-Romero
P. Pérez-Romero
ABA. Bulnes-Ramos
A. Bulnes-Ramos
JTJ. Torre-Cisneros
J. Torre-Cisneros
JGJ. Gavaldá
J. Gavaldá
TATeresa Aydillo
Teresa Aydillo
JOJ. Origuen
J. Origuen